Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1974 Jun;51(2):179–185. doi: 10.1111/j.1476-5381.1974.tb09645.x

Effects of tiprenolol, practolol and propranolol on experimental ventricular tachyarrhythmias

JD Allen, RG Shanks
PMCID: PMC1776753  PMID: 4155971

Abstract

1 Low doses of tiprenolol (0.01-0.02 mg/kg) and propranolol (0.05 mg/kg) abolished the ventricular arrhythmias produced by the intravenous injection of adrenaline in anaesthetized dogs respired with halothane.

2 Larger doses of tiprenolol (2.0-4.0 mg/kg) restored sinus rhythm in four of five dogs with ventricular tachycardia produced by toxic doses of ouabain. Propranolol (2.0-4.0 mg/kg) had the same effect in each of four dogs.

3 Both tiprenolol (4.0-8.0 mg/kg) and propranolol (4.0 mg/kg) increased the frequency of sinus beats and reduced the ventricular rate in dogs with ventricular tachycardia 20-44 h after ligation of a coronary artery.

4 Practolol (0.5-16.0 mg/kg) did not reduce the ventricular rate or increase the frequency of sinus beats in dogs with ventricular tachycardia after ligation of a coronary artery.

5 In dogs with ouabain-induced ventricular tachycardia mean arterial pressure was reduced after the administration of tiprenolol (0.5-8.0 mg/kg) or propranolol (4.0-8.0 mg/kg). Depression of sinus and atrioventricular nodal function, and of intraventricular conduction developed in some of the dogs given tiprenolol (4-8 mg/kg) or propranolol (8.0 mg/kg).

6 The administration of tiprenolol (1.0-8.0 mg/kg) or propranolol (4.0-8.0 mg/kg) depressed the arterial pressure and caused the deaths of some dogs in which a coronary artery had been ligated. Such deaths did not occur in the group which had been given toxic doses of ouabain.

Full text

PDF
179

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen J. D., Ekue J. M., Shanks R. G., Zaidi S. A. The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol. 1972 Aug;45(4):561–573. doi: 10.1111/j.1476-5381.1972.tb08114.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Allen J. D., Shanks R. G., Zaidi S. A. Effects of lignocaine and propranolol on experimental cardiac arrhythmias. Br J Pharmacol. 1971 May;42(1):1–12. doi: 10.1111/j.1476-5381.1971.tb07081.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dunlop D., Shanks R. G. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother. 1968 Jan;32(1):201–218. doi: 10.1111/j.1476-5381.1968.tb00444.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Epstein S. E., Braunwald E. Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med. 1966 Nov 24;275(21):1175–concl. doi: 10.1056/NEJM196611242752108. [DOI] [PubMed] [Google Scholar]
  5. Floor-Wieringa A., Van Strik R., Kesteloot H., Sluyts R. Effect of beta-receptor blocking drugs on the heart rate during submaximal exercise. Eur J Pharmacol. 1970;10(3):303–310. doi: 10.1016/0014-2999(70)90199-8. [DOI] [PubMed] [Google Scholar]
  6. Gianelly R. E., Goldman R. H., Treister B., Harrison D. C. Propranolol in patients with angina pectoris. Ann Intern Med. 1967 Dec;67(6):1216–1225. doi: 10.7326/0003-4819-67-6-1216. [DOI] [PubMed] [Google Scholar]
  7. Gibson D., Sowton E. The use of beta-adrenergic receptor blocking drugs in dysrhythmias. Prog Cardiovasc Dis. 1969 Jul;12(1):16–39. doi: 10.1016/0033-0620(69)90033-4. [DOI] [PubMed] [Google Scholar]
  8. Jewitt D. E., Mercer C. J., Shillingford J. P. Practolol in the treatment of cardiac dysrhythmias due to acute myocardial infarction. Lancet. 1969 Aug 2;2(7614):227–230. doi: 10.1016/s0140-6736(69)90001-4. [DOI] [PubMed] [Google Scholar]
  9. Kesteloot H., Sluyts R., Floor-Wieringa A., van Strik R. Pharmacological studies with tiprenolol and propranolol in man. Eur J Pharmacol. 1973 Mar;21(3):257–263. doi: 10.1016/0014-2999(73)90124-6. [DOI] [PubMed] [Google Scholar]
  10. Kreus K. E., Salokannel S. J., Isomäki H., Waris E. K. Alprenolol in the treatment of arrhythmias in acute coronary patients. Acta Med Scand. 1970 Nov;188(5):375–378. doi: 10.1111/j.0954-6820.1970.tb08053.x. [DOI] [PubMed] [Google Scholar]
  11. Laddu A. R., Somani P. Antiarrhythmic actions of 4-(2-hydroxy-3-isopropylaminopropoxy)-acetanilide (ICI 50,172) in the dog heart-lung preparation. J Pharmacol Exp Ther. 1969 Nov;170(1):79–83. [PubMed] [Google Scholar]
  12. Lucchesi B. R., Iwami T. The antiarrhythmic properties of ICI 46037, a quaternary analog of propranolol. J Pharmacol Exp Ther. 1968 Jul;162(1):49–59. [PubMed] [Google Scholar]
  13. Prichard B. N., Gillam P. M. Treatment of hypertension with propranolol. Br Med J. 1969 Jan 4;1(5635):7–16. doi: 10.1136/bmj.1.5635.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Roelandt J., Schamroth L., Hugenholtz P. G. Effects of new beta-blocking agent (DL-tiprenolol) on conduction within normal and anomalous atrioventricular pathways in Wolff-Parkinson-White syndrome. Br Heart J. 1972 Dec;34(12):1272–1282. doi: 10.1136/hrt.34.12.1272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sandler G., Pistevos A. C. Use of oxprenolol in cardiac arrhythmias associated with acute myocardial ischaemia. Br Med J. 1971 Jan 30;1(5743):254–257. doi: 10.1136/bmj.1.5743.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shanks R. G., Hadden D. R., Lowe D. C., McDevitt D. G., Montgomery D. A. Controlled trial of propranolol in thyrotoxicosis. Lancet. 1969 May 17;1(7603):993–994. doi: 10.1016/s0140-6736(69)91797-8. [DOI] [PubMed] [Google Scholar]
  17. Stephen S. A. Unwanted effects of propranolol. Am J Cardiol. 1966 Sep;18(3):463–472. doi: 10.1016/0002-9149(66)90071-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES